Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: Implications for drug safety assessment

Molecular Pharmacology

Volumn 76, Issue 4, 2009, Pages 710-722

  Huang, Xi Ping ^a,b   Setola, Vincent ^a,b   Yadav, Prem N ^a   Allen, John A ^a   Rogan, Sarah C ^a   Hanson, Bonnie J ^c   Revankar, Chetana ^c   Robers, Matt ^c   Doucette, Chris ^c   Roth, Bryan L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 4 AMINO 1 (6 CHLORO 2 PYRIDYL)PIPERIDINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; 8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; CABERGOLINE; CP 118952; CP 123479 11; CP 132484 42; DIHYDROERGOTAMINE; ERGOMETRINE; ERGOTAMINE; FENFLURAMINE; FENOLDOPAM; GUANFACINE; METHYLERGOMETRINE; METHYSERGIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NORFENFLURAMINE; OXYMETAZOLINE; PERGOLIDE; QUINIDINE; QUIPAZINE; ROPINIROLE; SEROTONIN; SEROTONIN 2 AGONIST; UNCLASSIFIED DRUG; XYLOMETAZOLINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

CELL LINE; CLUSTER ANALYSIS; HEART VALVE DISEASES; HUMANS; PHOSPHORYLATION; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70349310091     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.058057     Document Type: Article

References (23)

1. Berger M, Gray JA, and Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355-366.
2. Bourdon DM, Wing MR, Edwards EB, Sondek J, and Harden TK (2006) Quantification of isozyme-specific activation of phospholipase C-beta2 by Rac GTPases and phospholipase C-epsilon by Rho GTPases in an intact cell assay system. Methods Enzymol 406:489-499. (Pubitemid 43207462)
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 337:581-588. (Pubitemid 27360757)
5. Droogmans S, Cosyns B, D'haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, et al. (2007) Possible association between 3,4- methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100:1442-1445.
6. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, and Slocum N (2008) 5-Hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60:253-262.
7. Elangbam CS, Lightfoot RM, Yoon LW, Creech DR, Geske RS, Crumbley CW, Gates LD, and Wall HG (2005) 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 53:671-677.
8. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, et al. (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81. (Pubitemid 30033262)
9. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, et al. (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656-662. (Pubitemid 39173018)
10. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, and Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312.
11. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, and Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280-1286. (Pubitemid 35403801)
12. Regard JB, Sato IT, and Coughlin SR (2008) Anatomical profiling of G proteincoupled receptor expression. Cell 135:561-571.
13. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6-9.
14. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841. (Pubitemid 30954319)
15. Schade R, Andersohn F, Suissa S, Haverkamp W, and Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38. (Pubitemid 46041751)
16. Setola V, Dukat M, Glennon RA, and Roth BL (2005) Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 68:20-33. (Pubitemid 41002941)
17. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229. (Pubitemid 36627216)
18. Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hufeisen SJ, Leahy P, Brüning JC, and Roth BL (2006) p90 ribosomal S6 kinase 2 exerts a tonic brake on G proteincoupled receptor signaling. Proc Natl Acad Sci U S A 103:4717-4722.
19. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, and APD356-004 Study Group (2009) Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 17:494-503.
20. Steffee CH, Singh HK, and Chitwood WR (1999) Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8:245-253.
21. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, et al. (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577-587. (Pubitemid 351574813)
22. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
23. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, and Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46. (Pubitemid 46041752)